|
Multimodal Training Effects in Middle-Aged and Older Adults With Diabetic Sarcopenia
RECRUITINGN/ASponsored by yueh chu wu
Actively Recruiting
PhaseN/A
Sponsoryueh chu wu
Started2026-02-23
Est. completion2026-05-15
Eligibility
Age45 Years – 85 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07398495
Summary
This study aims to investigate the effects of a 12-week multimodal exercise intervention on middle-aged and older adults (aged 45\~85 years) with Type 2 Diabetes Mellitus (T2DM). The program combines supervised training, home-based sessions, and digital support to improve muscle function, physical performance, metabolic control, and quality of life.
Eligibility
Age: 45 Years – 85 YearsHealthy volunteers accepted
Inclusion Criteria: * Diagnosed with both Type 2 Diabetes Mellitus (T2DM) and sarcopenia. * Maintained on a stable regimen of oral hypoglycemic agents. * Aged 45 years or older. * Capable of communicating effectively in Mandarin or Taiwanese. * Willing to provide informed consent or have it obtained from a legally authorized representative. Exclusion Criteria: * • Limited limb or joint function that prevents exercise (e.g., recent fractures or dislocations). * Communication barriers or severe emotional/psychological issues (e.g., uncontrolled depression or severe mental illness). * Severe cognitive impairment (e.g., dementia). * End-stage renal disease (ESRD). * Major comorbidities or complications, including active diabetic foot ulcers, amputation, recent myocardial infarction, severe autonomic neuropathy, or a history of stroke within the last 3 years.
Conditions3
DiabetesSarcopeniaType 2 Diabetes Mellitus (T2DM)
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhaseN/A
Sponsoryueh chu wu
Started2026-02-23
Est. completion2026-05-15
Eligibility
Age45 Years – 85 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07398495